$42,000-a-year HIV vaccine trialed in Africa

The manufacturer claims the drug has a 100% prevention rate in women

US biopharmaceutical company Gilead Sciences Inc. has claimed that an experimental vaccine has demonstrated 100% efficacy for the prevention of HIV infections in women, after conducting trials in South Africa and Uganda  

Trials with the twice-yearly ‘lenacapavir’ shot involved about 5,300 women aged between 16 and 25, the company announced last week. Some were...